Routes of
administration Oral CAS Number 1312547-19-5 KEGG D10665 Molar mass 885.062 g/mol ChemSpider ID 30843806 | Legal status Investigational PubChem CID 53302707 Formula C47H48N8O6S2 Pubchem 53302707 | |
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.
Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex. While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.